Evidence map›Paper›PMID 40165716›Full record

ArticleJournal of cosmetic dermatology2025

Influential Factors in the Efficacy and Safety of Hemoporfin-Mediated Photodynamic Therapy for Facial Port-Wine Stains.

Ruixuan You, Yixin Tan, Xueqin Zhang, Lu Li, Ting Zeng, Yixin Zhou, Yaqian Shi, Yongqi Shao, Hongxia Yan, Rong Xiao and 1 more

Abstract read
In one paragraph

Article in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Noninvasive Diagnosis Revealed a Strong Therapeutic Response and Skin Barrier Changes in Hemoporfin-Mediated Photodynamic Therapy for Port-Wine Stains.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2026
    Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ruixuan YouDepartment of Dermatology, The Second Xiangya Hospital of Central South University, Changsha, China.
Yixin TanDepartment of Dermatology, The Second Xiangya Hospital of Central South University, Changsha, China.
Xueqin ZhangDepartment of Dermatology, The Second Xiangya Hospital of Central South University, Changsha, China.
Lu LiDepartment of Dermatology, The Second Xiangya Hospital of Central South University, Changsha, China.
Ting ZengDepartment of Dermatology, The Second Xiangya Hospital of Central South University, Changsha, China.
Yixin ZhouDepartment of Dermatology, The Second Xiangya Hospital of Central South University, Changsha, China.
Yaqian ShiDepartment of Dermatology, The Second Xiangya Hospital of Central South University, Changsha, China.
Yongqi ShaoDepartment of Dermatology, The Second Xiangya Hospital of Central South University, Changsha, China.
Hongxia YanDepartment of Dermatology, The Second Xiangya Hospital of Central South University, Changsha, China.
Rong XiaoDepartment of Dermatology, The Second Xiangya Hospital of Central South University, Changsha, China.ORCID https://orcid.org/0000-0002-6214-8057
Xiangning QiuDepartment of Dermatology, The Second Xiangya Hospital of Central South University, Changsha, China.

Funding

Hunan Provincial Health High-Level Talent Scientific Research Project R2023024National Natural Science Foundation of China 82373486Natural Science Foundation of Hunan Province 2024JJ9199
6 · The paper itself

Abstract

backgroundHemoporfin-mediated photodynamic therapy (HMME-PDT) is a novel and promising treatment for port-wine stains (PWS); however, the factors affecting the efficacy and safety are controversial.

aimIn this study, the relationship between influential factors and the efficacy and safety of HMME-PDT for facial PWS was clarified.

methodsIn this retrospective study, 155 patients suffering from facial PWS who underwent HMME-PDT at 2-3 months interval were included. The efficacy was evaluated by the facial PWS area and severity index (FSASI) scoring system based on pre- and post-treatment photographs of the lesion. The demographic characteristics, lesion patterns, treatment history, number of treatment sessions, and adverse events were also recorded.

resultsAfter the first and second sessions of HMME-PDT, 61.9% and 92.9% of patients responded, respectively. The lesion subtype, degree of lip involvement, and number of HMME-PDT sessions were associated with the efficacy of HMME-PDT (p = 0.014, p = 0.034, p < 0.001, and respectively). Logistic regression analysis confirmed that the patients with red-type PWS (p = 0.019) and more HMME-PDT sessions (≥ 2) (p < 0.001) showed an association with a better response to HMME-PDT. The response rate was higher for lesions on the mandibular prominence area than that on the forehead area (p = 0.031). No photosensitivity or systemic adverse reactions were reported. Most adverse effects were well tolerated in all patients. Furthermore, the severity of crust was found positively associated with the efficacy (p < 0.001).

conclusionHMME-PDT is an effective and safe treatment approach for treating facial PWS. Patients who had red-type, nonforehead area, and more treatment sessions showed an association with better efficacy.

Indexed as

HematoporphyrinsPhotochemotherapyPhotosensitizing AgentsPort-Wine StainAdolescentAdultChildChild, PreschoolFaceFacial DermatosesFemaleHumansMaleMiddle AgedRetrospective StudiesSeverity of Illness Indexhematoporphyrin monomethyl etherHematoporphyrinsPhotosensitizing Agentsefficacyhemoporfinphotodynamic therapyport‐wine stainsafety

Identifiers

PMID40165716
PMCPMC11959330

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.